Campbell Family Cancer Research Institute, Ontario Cancer Institute, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Clin Exp Ophthalmol. 2014 Jan-Feb;42(1):33-52. doi: 10.1111/ceo.12132. Epub 2013 May 22.
Retinoblastoma is a paediatric ocular tumour that continues to reveal much about the genetic basis of cancer development. Study of genomic aberrations in retinoblastoma tumours has exposed important mechanisms of cancer development and identified oncogenes and tumour suppressors that offer potential points of therapeutic intervention. The recent development of next-generation genomic technologies has allowed further refinement of the genomic landscape of retinoblastoma at high resolution. In a relatively short period of time, a wealth of genetic and epigenetic data has emerged on a small number of tumour samples. These data highlight the inherent molecular complexity of this cancer despite the fact that most retinoblastomas are initiated by the inactivation of a single tumour suppressor gene. This review outlines the current understanding of the genomic, genetic and epigenetic changes in retinoblastoma, highlighting recent genome-wide analyses that have identified exciting candidate genes worthy of further validation as potential prognostic and therapeutic targets.
视网膜母细胞瘤是一种小儿眼部肿瘤,它不断揭示癌症发展的遗传基础。对视网膜母细胞瘤肿瘤中基因组异常的研究揭示了癌症发展的重要机制,并确定了癌基因和肿瘤抑制基因,为治疗干预提供了潜在的靶点。新一代基因组技术的最新发展使得能够以高分辨率进一步细化视网膜母细胞瘤的基因组图谱。在相对较短的时间内,仅少数肿瘤样本就产生了大量的遗传和表观遗传数据。尽管大多数视网膜母细胞瘤是由单个肿瘤抑制基因失活引起的,但这些数据突出了这种癌症固有的分子复杂性。本综述概述了对视网膜母细胞瘤中基因组、遗传和表观遗传变化的现有认识,强调了最近的全基因组分析,这些分析确定了令人兴奋的候选基因,值得进一步验证,作为潜在的预后和治疗靶点。